Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515858 | 0.83 | MAPT (0.42) | KDM4E | |
| SCHEMBL3514876 | 0.83 | CNR2 (0.44) | PTGDR2CNR1CNR2MEN1KMT2A | |
| SCHEMBL16238692 | 0.82 | CNR2 (0.46) | PTGDR2CNR1CNR2MEN1KMT2A | |
| SCHEMBL3515010 | 0.81 | MAPT (0.41) | KDM4E | |
| SCHEMBL3515392 | 0.81 | KDM4E (0.39) | CNR1CNR2MEN1KMT2AKDM4E | |
| SCHEMBL1522959 | 0.80 | KDM4E (0.53) | CNR1CNR2MEN1KMT2AKDM4E | |
| SCHEMBL3515995 | 0.80 | ALDH1A1 (0.44) | CNR1CNR2MEN1KMT2AKDM4E | |
| SCHEMBL3516729 | 0.79 | HIF1A (0.50) | CNR1CNR2MEN1KMT2AKDM4E | |
| SCHEMBL3517649 | 0.77 | PTGDR2 (0.48) | PTGDR2 | |
| SCHEMBL4324294 | 0.77 | ALDH1A1 (0.40) | PTGDR2CNR1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| EP-2044068-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | Merck & Co., Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010964-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | PTGDR2 4549/4885CNR1 4017/4885CNR2 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.